Matthew Price, COO of Promontory Therapeutics is an experienced biotech entrepreneur / C-level executive, and the only company co-founder named a 2022 Emerging Pharma Leader by Pharmaceutical Executive. He is responsible for industry collaborations with Pfizer and Merck KGaA, and for Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute.

Robert Jacks, has 20 years of experience in the biopharmaceutical industry. He has founded or co-founded multiple companies and raised more than $170 million with several successful exits.

Dr. Marcelo Bigal, President and CEO of Ventus Therapeutics, a company that expects to become the leader in the field of using precision medicine to identify subsets of patients with severe chronic neurological conditions.

Vlad Vitoc is the Founder & CEO of MAIA, an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Vlad and his team took MAIA public successfully in 2022 in one of the most difficult IPO markets in recent years.

Hans Keirstead, is a serial entrepreneur and currently the Founder, CEO and Chairman of Aivita Biomedical, a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer. He has now founded four biotechnology companies with successful exits in his previous three companies. Dr. Keirstead also holds Board positions in several prominent biotechnology companies.

Mani Mohindru, CEO of Novasenta has a non-traditional career path, starting as a scientist studying immune cells in the context of autoimmune diseases. She later worked in investment banking, which exposed her to different therapeutic areas, treatment modalities, and a full view of what a company can grow into. She then transitioned to the operations side of public biotechs as Chief Strategy Officer and eventually became a Chief Financial Officer before becoming the CEO of Novasena.

Brian Finrow is the CEO of Lumen Bioscience, where they are reinventing how biologic drugs are made. Unlike to a lot of Bioscience CEO’s, Brian comes from the legal industry having spent over 8 years at Cooley. Lumen's patented technology allows them to use the well-known food algae spirulina to deliver therapeutic proteins.